Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)

Parkinson Disease Clinical Trial

— AWAKENING  

Official title:

Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING Device : AWAKENING Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06401395
• Other study ID #: DigiParkMonitor_1.0_Awakening
• Secondary ID: 2024-A00464-43
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2024
• Est. completion date: August 1, 2027

Study information

• Verified date: April 2024
• Source: DIAMPARK
• Contact: Magali BALAVOINE
• Phone: +33241682940
• Email: m.balavoine[@]ilcgroupe.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease (PD) ranks second among neurodegenerative diseases and is a major cause of neurological motor disability. The number of PD cases doubled between 1990 and 2016. The consequences of PD, including an increased risk of falls, loss of autonomy and reduced quality of life, contribute to increased morbidity and mortality. The costs associated with falls in the elderly (a fortiori those with PD) and their consequences represent between 0.85% and 1.5% of total healthcare expenditure.

There is currently no cure for PD. Treatment is symptomatic and depends on the degree of functional impairment and the age of onset. After a period of stabilization (state phase) of varying length, the clinical situation worsens because of treatment-related motor complications (motor fluctuations, on/off phenomena, dyskinesias, under/overdosing) and the appearance or worsening of disease-specific signs linked to the pathogenic process. Treatment of motor complications involves constantly adjusting doses and dosing schedules to suit each individual case, and to take account of variations in the patient's motor status over the months. These adjustments must also take into account the non-motor signs of the disease, notably thymic fluctuations, treatment-related behavioral disorders, fatigue, sensory and pain disorders. Regular follow-up of patients is therefore essential to assess the evolution of their symptoms, adjust treatment, adapt therapeutic interventions and improve their quality of life. However, most consultations with the neurologist are bi-annual, and because of the long time lapse between two consultations, the practitioner often has only incomplete information on the evolution of symptoms.

To help fill these gaps, advances in digital health technologies, with the development of telemonitoring solutions, enable patients to be monitored remotely and provide a potentially more robust amount of information relating to the severity of the disease and its evolution over time. In this sense, remote monitoring in PD would enable the neurologist to readjust treatment at the right time and in the most appropriate way. This will be done by means of a weekly questionnaire (adapted from the clinical examination via the MDS-UPDRS scale) completed by the patient via a mobile application.

Remote monitoring of patients should improve their symptom management and quality of life, hence the interest in an intervention offering a remote monitoring service: DIGIPARK MONITOR.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: August 1, 2027
• Est. primary completion date: January 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years ;

• Parkinson's disease according to MDS diagnostic criteria ;

• Classified as stage 1.5 to 3 according to the Hoehn and Yahr stages ;

• Followed by a neurologist since at least one month;

• Equipped with a smartphone or a computer or tablet with internet/cellular data access via the latter (or with the caregiver) ;

• Resident on French territory affiliated to a social security scheme.

Exclusion Criteria:

• Person under guardianship, curatorship or safeguard of justice or any other administrative or judicial measure of deprivation of rights and freedom;

• Patient suffering from dementia, mental disorders, cognitive disorders, or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the study protocol;

• Patient deemed non-autonomous by the investigator and without a caregiver;

• Patient already included in another interventional research study, with the exception of NS-PARK's "PRECISE-PD" cohort.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Device:
• DIGIPARK MONITOR
remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.

Locations

Country	Name	City	State
France	CHU Angers	Angers
France	CH Flayriat	Bourg-en-Bresse
France	CHU Caen	Caen
France	Clinique du Plateau	Clamart
France	CH Emile Roux	Le Puy-en-Velay
France	Clinique Beau Soleil	Montpellier
France	CHU Nice	Nice
France	CH de Troyes	Troyes
France	Hopital jean Bernard	Valenciennes
France	Médipole Hôpital Mutuliste	Villeurbanne

Sponsors (3)

Lead Sponsor	Collaborator
DIAMPARK	Digital Medical Hub, Weprom

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical effectiveness of telemonitoring on symptom progression in PD patients assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)	total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration	6 months
Secondary	Evolution of PD patients' symptoms assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)	Total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration	12 months
Secondary	Specific quality of Life assessed by Parkinson Disease Questionnaire (PD-Q39).	score of Parkinson Disease Questionnaire (PD-Q39). Score range from 0 to 100. A high score indicates a deterioration	12 months
Secondary	General quality of Life assessed by EuroQol-5 dimensions questionnaire	Score of EuroQol-5 dimensions questionnaire. Score range from 0 to 100. A high score indicates a improvement	12 months
Secondary	Organizational impact assessed by the number of consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations	Percentage of patients who had a consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations	12 months
Secondary	Medico-economic impact	Average total cost at 12 months in each group	12 months
Secondary	Usability assessed by System Usability Scale.	System Usability Scale. Score range from 1 to 100. A high score indicates a improvement	12 months
Secondary	User's satisfaction assessed by a spécific questionnaire created for the study	Satisfaction questionnaire created specifically for the study.Score range from 1 to 100. A high score indicates a improvement	12 months